{"id":"exatecan","rwe":[{"pmid":"41638011","year":"2026","title":"Trimethyl Lock-2Cl (TML-2Cl): A self-cyclizing adapter for molecular release in antibody-drug conjugates.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41629825","year":"2026","title":"GSTP1 as a novel protective target in sepsis: evidence from proteome-wide Mendelian randomization and multi-omics analyses.","finding":"","journal":"BMC infectious diseases","studyType":"Clinical Study"},{"pmid":"41609209","year":"2026","title":"Identification and Pre-clinical Evaluation of a Novel GD2 Antibody-Drug Conjugate for Solid Tumors in Children and Adults.","finding":"","journal":"Molecular cancer therapeutics","studyType":"Clinical Study"},{"pmid":"41599111","year":"2025","title":"Ultrasound-Sensitive Liposomal Exatecan for Tumor-Specific Drug Release for Treatment of Pancreatic Cancer.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"41497307","year":"2025","title":"Hypoxia-responsive Exatecan prodrug liposomes co-delivered with IR808 for synergistic chemo-photodynamic therapy of breast cancer.","finding":"","journal":"International journal of pharmaceutics: X","studyType":"Clinical Study"}],"tags":[{"label":"exatecan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase I Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["exatecan","DX 8951","DX-8951a","DX-8951f","exatecan mesylate","exatecan hydrochloride"],"offLabel":[],"synonyms":["exatecan","DX 8951","DX-8951a","DX-8951f","exatecan mesylate","exatecan hydrochloride"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"exatecan","explanation":"Imagine your DNA is a long piece of string that needs to be unwound so that new cells can grow. Topoisomerase I is the enzyme that helps to unwind this string. EXATECAN blocks this enzyme, which can prevent cancer cells from growing and dividing.","oneSentence":"EXATECAN works by inhibiting topoisomerase I, an enzyme involved in DNA replication and repair.","technicalDetail":"EXATECAN is a topoisomerase I inhibitor that acts by binding to the enzyme and preventing it from participating in DNA replication and repair, thereby inducing DNA damage and apoptosis in rapidly dividing cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1120","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EXATECAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EXATECAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:12:07.459538","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:41:47.979032+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"exatecan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05691517","phase":"PHASE1","title":"Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-12","conditions":["Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm"],"enrollment":35,"completionDate":"2026-10-15"},{"nctId":"NCT07360314","phase":"PHASE1","title":"Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-02-13","conditions":["Advanced Solid Tumors"],"enrollment":138,"completionDate":"2029-03-28"},{"nctId":"NCT06641908","phase":"PHASE1","title":"Anti-GD2 ADC M3554 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-11-08","conditions":["Advanced Solid Tumor"],"enrollment":52,"completionDate":"2027-04-16"},{"nctId":"NCT07454642","phase":"PHASE1","title":"AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors","status":"RECRUITING","sponsor":"Avacta Life Sciences Ltd","startDate":"2026-03","conditions":["Vulvar Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Small Cell Carcinoma of Lung"],"enrollment":144,"completionDate":"2030-06"},{"nctId":"NCT05865990","phase":"PHASE2","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-11-24","conditions":["Metastatic Breast Cancer","Advanced Non-Small Cell Squamous Lung Cancer","Solid Tumor, Adult"],"enrollment":63,"completionDate":"2026-10"},{"nctId":"NCT06048718","phase":"PHASE2","title":"T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2024-06-05","conditions":["Breast Cancer","Metastatic Breast Cancer"],"enrollment":28,"completionDate":"2026-11"},{"nctId":"NCT06781983","phase":"PHASE1","title":"Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Innate Pharma","startDate":"2025-01-24","conditions":["Advanced or Metastatic Solid Tumors"],"enrollment":145,"completionDate":"2029-04"},{"nctId":"NCT06545617","phase":"PHASE1,PHASE2","title":"A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer","status":"WITHDRAWN","sponsor":"Bio-Thera Solutions","startDate":"2025-01-31","conditions":["Platinum-resistant Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"enrollment":0,"completionDate":"2028-01-31"},{"nctId":"NCT05378737","phase":"PHASE1","title":"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-06","conditions":["Advanced Solid Tumors"],"enrollment":216,"completionDate":"2025-12-08"},{"nctId":"NCT06730100","phase":"PHASE2","title":"CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-17","conditions":["Metastatic Mismatch Repair Proficient Colorectal Carcinoma","Refractory Mismatch Repair Proficient Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v8"],"enrollment":0,"completionDate":"2026-12-01"},{"nctId":"NCT06315491","phase":"PHASE2","title":"A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Cybrexa Therapeutics","startDate":"2024-09-25","conditions":["Platinum-resistant Ovarian Cancer","Refractory Ovarian Carcinoma"],"enrollment":40,"completionDate":"2025-10"},{"nctId":"NCT07152782","phase":"PHASE2","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11","conditions":["Breast Cancer With Brain Metastasis","HER2-positive Breast Cancer"],"enrollment":202,"completionDate":"2029-11"},{"nctId":"NCT07150208","phase":"PHASE2","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":["Breast Cancer With Brain Metastasis","HER2-low Expressing Breast Cancer"],"enrollment":140,"completionDate":"2028-09"},{"nctId":"NCT06676917","phase":"PHASE2","title":"Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases","status":"WITHDRAWN","sponsor":"MedSIR","startDate":"2025-06","conditions":["Non-small Cell Lung Cancer"],"enrollment":0,"completionDate":"2027-08"},{"nctId":"NCT05879627","phase":"PHASE1","title":"To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2023-01-17","conditions":["Advanced Solid Tumors"],"enrollment":250,"completionDate":"2026-07-01"},{"nctId":"NCT04902872","phase":"PHASE1,PHASE2","title":"Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cybrexa Therapeutics","startDate":"2021-05-03","conditions":["Solid Tumor, Adult","Epithelial Ovarian Cancer","Small Cell Lung Carcinoma","Breast Cancer","Colorectal Cancer","Pancreas Cancer","Appendix Cancer","Non-small Cell Lung Cancer","Gastric Cancer","Esophagus Cancer","Urothelial Carcinoma","Sarcoma"],"enrollment":130,"completionDate":"2025-06"},{"nctId":"NCT05622591","phase":"PHASE1","title":"ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML","status":"WITHDRAWN","sponsor":"Elucida Oncology","startDate":"2024-06-07","conditions":["Acute Myeloid Leukemia","AML, Childhood","Relapsed Pediatric AML","Refractory Pediatric AML"],"enrollment":0,"completionDate":"2024-06-07"},{"nctId":"NCT05001282","phase":"PHASE1,PHASE2","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","status":"TERMINATED","sponsor":"Elucida Oncology","startDate":"2021-09-13","conditions":["Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Endometrial Cancer","Ovary Cancer","Ovary Neoplasm","Ovary Disease","Ovary Metastasis","Ovarian Diseases","Ovarian Cancer Stage","Ovarian Epithelial Cancer","Ovarian Adenocarcinoma","Ovarian Serous Adenocarcinoma","Ovarian Neoplasm Epithelial","Ovarian Cancer Recurrent","Endometrial Diseases","Endometrial Adenocarcinoma","Endometrial Carcinosarcoma","Endometrial Clear Cell Adenocarcinoma","Endometrioid Adenocarcinoma","Endometrial Neoplasms","Endometrial Cancer Recurrent","Endometrioid Tumor","Fallopian Tube Cancer","Peritoneal Cancer"],"enrollment":79,"completionDate":"2024-06-07"},{"nctId":"NCT06328387","phase":"PHASE1,PHASE2","title":"HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-29","conditions":["Advanced Breast Cancer","Metastatic Breast Cancer"],"enrollment":120,"completionDate":"2026-03-01"},{"nctId":"NCT05405621","phase":"PHASE1","title":"Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009","status":"UNKNOWN","sponsor":"Bio-Thera Solutions","startDate":"2022-08-02","conditions":["Locally Advanced/Metastatic Solid Tumours"],"enrollment":48,"completionDate":"2024-12"},{"nctId":"NCT00045318","phase":"PHASE1","title":"Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2002-05","conditions":["Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":"2007-10"},{"nctId":"NCT00005091","phase":"PHASE2","title":"DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Daiichi Pharmaceuticals","startDate":"1999-02","conditions":["Lung Cancer"],"enrollment":0,"completionDate":"2003-08"},{"nctId":"NCT00041236","phase":"PHASE2","title":"Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-05","conditions":["Sarcoma"],"enrollment":39,"completionDate":""},{"nctId":"NCT00003951","phase":"PHASE2","title":"DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-06","conditions":["Pancreatic Cancer"],"enrollment":37,"completionDate":"2005-04"},{"nctId":"NCT00004866","phase":"PHASE2","title":"DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2000-01","conditions":["Cervical Cancer"],"enrollment":0,"completionDate":"2003-09"},{"nctId":"NCT00055939","phase":"PHASE2","title":"Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2003-01","conditions":["Sarcoma"],"enrollment":0,"completionDate":"2006-04"},{"nctId":"NCT00004060","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-07","conditions":["Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer"],"enrollment":0,"completionDate":"2000-09"},{"nctId":"NCT00005938","phase":"PHASE2","title":"DX-8951f in Treating Patients With Biliary Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2000-03","conditions":["Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Liver Cancer"],"enrollment":0,"completionDate":"2005-04"},{"nctId":"NCT00017212","phase":"PHASE2","title":"DX-8951f in Treating Patients With Metastatic Stomach Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2001-04","conditions":["Esophageal Cancer","Gastric Cancer"],"enrollment":0,"completionDate":"2003-09"},{"nctId":"NCT00004046","phase":"PHASE2","title":"Chemotherapy in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-06","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2002-04"},{"nctId":"NCT00004108","phase":"PHASE2","title":"DX-8951f in Treating Patients With Liver Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-09","conditions":["Liver Cancer"],"enrollment":0,"completionDate":"2005-04"},{"nctId":"NCT00055952","phase":"PHASE2","title":"Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2003-01","conditions":["Sarcoma"],"enrollment":0,"completionDate":"2006-04"},{"nctId":"NCT00023972","phase":"PHASE3","title":"Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2001-07","conditions":["Pancreatic Cancer"],"enrollment":0,"completionDate":"2005-04"},{"nctId":"NCT00004047","phase":"PHASE1","title":"Chemotherapy in Treating Patients Who Have Hematologic Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-06","conditions":["Leukemia","Myelodysplastic Syndromes"],"enrollment":0,"completionDate":"2005-04"},{"nctId":"NCT00004212","phase":"PHASE1","title":"DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-09","conditions":["Brain and Central Nervous System Tumors","Lymphoma","Unspecified Childhood Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":"2004-04"},{"nctId":"NCT00004045","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"1999-06","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2001-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"OC71PP0F89","CHEBI":"CHEBI:135709","INN_ID":"7887","UMLSCUI":"C0965941","ChEMBL_ID":"CHEMBL1614650","DRUGBANK_ID":"DB12185","PUBCHEM_CID":"151115","SECONDARY_CAS_RN":"197720-53-9","MESH_SUPPLEMENTAL_RECORD_UI":"C095887"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"6.7 hours","clearance":"0.96 mL/min/kg","volumeOfDistribution":"0.44 L/kg"},"publicationCount":128,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 15","pmid":"41638011","title":"Trimethyl Lock-2Cl (TML-2Cl): A self-cyclizing adapter for molecular release in antibody-drug conjugates.","journal":"European journal of medicinal chemistry"},{"date":"2026 Feb 2","pmid":"41629825","title":"GSTP1 as a novel protective target in sepsis: evidence from proteome-wide Mendelian randomization and multi-omics analyses.","journal":"BMC infectious diseases"},{"date":"2026 Jan 29","pmid":"41609209","title":"Identification and Pre-clinical Evaluation of a Novel GD2 Antibody-Drug Conjugate for Solid Tumors in Children and Adults.","journal":"Molecular cancer therapeutics"},{"date":"2025 Dec 19","pmid":"41599111","title":"Ultrasound-Sensitive Liposomal Exatecan for Tumor-Specific Drug Release for Treatment of Pancreatic Cancer.","journal":"Pharmaceutics"},{"date":"2025 Dec","pmid":"41497307","title":"Hypoxia-responsive Exatecan prodrug liposomes co-delivered with IR808 for synergistic chemo-photodynamic therapy of breast cancer.","journal":"International journal of pharmaceutics: X"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"EXATECAN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EXATECAN is a small molecule drug in the exatecan class, originally developed by and currently owned by . It is used to treat certain conditions, but its exact target and approved indications are unknown. The drug has a half-life of 6.7 hours, but its bioavailability and commercial status are not publicly available. EXATECAN's safety profile and potential side effects are not well-documented, and it is unclear whether it is patented or available as a generic medication.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:41:47.979032+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}